Samvel Aleksanyan’s Post

🔍 Exciting news in biotech investments! These investments show the growing potential in biometrics. Great to see advancements across different health areas, from mental health to cancer treatment 🇺🇸 Spyre Therapeutics | $180 million PIPE | monoclonal antibodies | preclinical in inflammatory bowel disease 🇺🇸 Engrail Therapeutics | $157 million series B | precision neuroscience | phase 2 in generalized anxiety disorder 🇨🇦 Cybin Inc | $150 million PIPE | mental healthcare | phase 2 in major depressive disorder 🇩🇪 Tubulis GmbH | €128 million ($138.75 million) series B2 | antibody drug conjugates | preclinical in multiple solid tumors 🇺🇸 Unicycive Therapeutics | $50 million PIPE | kidney disease treatments | phase 1 in hyperphosphatemia 🇬🇧 Relation | $35 million seed | multi omics for drug discovery | discovery in osteoporosis 🇸🇪 Asgard Therapeutics | €30 million ($32.53 million) series A | cancer immunotherapies | preclinical in cancer 🇬🇧 Mission Therapeutics | £25.2 million ($32 million) | deubiquitylating enzyme inhibitors | phase 2 in cardiac surgery-associated kidney injury 🇺🇸 Elicio Therapeutics | $6 million PIPE | immunotherapies | phase 2 in pancreatic ductal adenocarcinoma

Who are some of the players looking to make a difference in the precision medicine space? 🎯 Precision medicine, which is a tailored treatment method taking into account an individual’s genetic makeup, environment and lifestyle, is being studied to potentially treat all kinds of diseases including cancer, metabolic diseases and neurological conditions. 🧬🔍 With a market value that is set to grow exponentially in the next few years, more and more biotechs are becoming immersed in the field. 📈 Read our latest article to discover seven precision medicine companies that you’ve got to watch out for! 👇 https://lnkd.in/dXbNVA6T #PrecisionMedicine #Biotech #Biopharma #Cancer #MetabolicDiseases #Neurodegeneration #BiotechStartups AC Immune | Alto Neuroscience | Biomea Fusion | Engine Biosciences | ReCode Therapeutics | Scorpion Therapeutics | SpringWorks Therapeutics | Novartis | Genoptix, Inc. | Pfizer | AstraZeneca | Amgen | Roche | Bristol Myers Squibb | BioNTech SE  

EvlaBio AG is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a therapeutic monoclonal antibody (mAb) targeting the FGF23/FGFR4 pathway for the treatment of left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF) in the setting of chronic kidney disease (CKD). LVH and HFpEF occur in CKD patients as a consequence of FGF23/FGFR4 overdrive. Hence, blocking the FGF23/FGFR4 interaction has the potential to prevent cardiac hypertrophy and ameliorate heart failure in patients with CKD. The serviceable obtainable market of patients with LVH due to FGF23/FGFR4 overdrive ranges between 5 and 6 M in the seven major markets, representing a substantial commercial opportunity. Based on its underlying mechanism of action, the EvlaBio approach is expected to be hemodynamically neutral. This is a critical differentiating feature from currently available treatment options. With respect to modality, the EvlaBio will be the first biologic developed for this indication, and it has the potential to be a first in class and first in indication therapy.  We also have a biomarker strategy leveraging specific features of target biology in place, ensuring effective clinical trial design. Meet EvlaBio AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

IPO fever seems to be setting in already! Last year only 22 drugmakers priced new offerings which was the lowest total in 6 years. Already in 2024, 5 companies have jumped into the mix meaning a much more promising start and giving an optimistic outlook for 2024 (hopefully!). ◼ Alto Neuroscience – 2 months after closing a $45 million Series C, they’re preparing an IPO to push precision psychiatry therapies through the clinic ◼ ArriVent Biopharma – hoping to net over $156 million to support the development of their drug for NSCLC patients ◼ CG Oncology – aiming for a $1 billion valuation to continue their work developing a therapy for patients with bladder cancer ◼ Kyverna Therapeutics – looking to fund their cell therapy work led by their experimental lupus treatment ◼ Metagenomi – last year they raised $275 million in their Series B and they have now filed to bring their work on identifying new CRISPR enzymes for gene editing, public I think this sets up 2024 to be a much better year than the last! Any thoughts? Let me know in the comments. #ipo #biotech #funding

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Atara Biotherapeutics to lay off 73 California employees by the end of the year: Atara Biotherapeutics is laying off 73 workers in California at the end of the year, a little less than a month after announcing a restructuring and a failed Phase II trial in multiple sclerosis. In November, Atara said it would be “undertaking a strategic restructuring” and reducing its workforce by 30% and expected its cash to fund the company into the third quarter of 2025. The biotech also reported a net loss of $69.8 million, or $0.66 per share, for the third quarter this year. According to a California WARN notice, 72 workers will be laid off at one location in Thousand Oaks, and one employee at a second location in the same city with an effective date of Dec. 31. Atara announced another thinning plan in 2022 when it laid off 77 employees at three different sites in California. This round of layoffs comes after the company said on Nov. 1 in its third quarter financial results that the restructuring would allow Atara to focus on its tab-cel (tabelecleucel) with Pierre Fabre Laboratories, its allogeneic CAR-T programs and the advancement of ATA188, its cell therapy candidate for progressive multiple sclerosis. But then on Nov. 8, Atara said that ATA188 flunked its Phase II study, missing the primary endpoint of disability improvement after 12 months as well as fluid and imaging biomarkers. The company said at the time of the trial flop that it would instead put the money toward its CAR-T pipeline and its partnership with Pierre Fabre, which is expected to bring in $30 million in cash upfront and another $100 million in potential regulatory milestones. Atara said it expects preliminary clinical data for its allogeneic T-cell therapy, ATA3219, in relapsed/refractory B-cell non-Hodgkin lymphoma in the second half of 2024 as well as “progressing efforts” toward a potential trial evaluating another autoimmune disease. #lucidquest #genetherapy #celltherapy

Ahead of the JP Morgan Healthcare Conference, Pangea Biomed and Pepper Bio, two VSC Ventures portfolio companies, discuss the future of precision medicine in The Wall Street Journal. More from Brian Gormley here: https://lnkd.in/enAKGuEe Tel Aviv-based Pangea Biomed is partnering with drugmakers seeking help with questions such as which cancers to target with treatments in clinical trials, according to CEO Tuvik Beker. Targeted cancer drugs are designed to treat patients with a specific gene mutation. Patients are tested for these mutations to determine whether they are likely to benefit. But this testing doesn’t tell the whole story, Beker said. Many other genes are also involved in a patient’s response, he said. Pangea, which has raised $12 million in venture capital, examines interaction patterns of many other related genes to predict if a drug will work or not. While its revenue now comes from partnerships with pharmaceutical companies, Pangea eventually aims to make its technology available to clinicians to aid treatment decisions for patients, Beker said. ## Cambridge, Mass.-based Pepper Bio’s “transomics” approach involves analyzing DNA, RNA, proteins and molecular switches on proteins in tumors, tissue in tumors’ immediate surroundings and adjacent healthy tissue, said Co-founder and CEO Jon Hu. The goal is to find drugs that act on molecular pathways that cause or sustain cancer and not on pathways that would lead to toxicity, he added. Pepper is looking to acquire drugs that target biological pathways in cancer that it has found to be promising avenues for treatments. “We don’t think the right question is if AI will impact drug discovery, but how and when,” Hu said. Tuvik Beker Ranit Aharonov Emmanuel Elalouf Jon (Yu) Hu Samantha Dale Strasser Omri Amirav-Drory NFX James Currier Pete Flint Riley Munks

🔬 Exciting Publication -->Apricell Biotechnology -->3-in-1 Plate! 🔬 Researchers utilized the 3D #tumoroid culture plate from Apricell Biotechnology Inc. to create a human-mimicked #Glioblastoma tumor model. This study aimed to evaluate the impact of #localized combination #drugdelivery on the #viability and invasive behavior of tumor #spheroids within a bio-mimicked #extracellularmatrix of the tumor site. https://lnkd.in/e74gjkcA 💡At Apricell Biotechnology Inc., we are committed to advancing scientific innovation and revolutionizing the way researchers conduct cell-based assays. 3-in-1 Plate offers a cutting-edge solution for creating physiologically relevant #3dcellculture models, facilitating #therapeutic screening, and accelerating #drugdiscovery efforts. We are proud to contribute to advancing cancer research and look forward to seeing the impact of our 3-in-1 plate on the future of #invitro human-mimicked #cancer models. For more information on our revolutionary range of products, including the 3-in-1 Plate, please visit our website or contact us directly at info@apricell.com. Let us work together to explore new possibilities in 3D cell culture and therapeutic discovery! #Microfluidics #organoids #DrugDiscovery #BiomedicalResearch #Innovation #Science #Publication #ResearchAdvancement

𝐋𝐢𝐪𝐮𝐢𝐝 𝐁𝐢𝐨𝐩𝐬𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $11.3 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2029 Download PDF Brochure @ https://lnkd.in/dDRBxwNW The report "𝐋𝐢𝐪𝐮𝐢𝐝 𝐁𝐢𝐨𝐩𝐬𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐛𝐲 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 & 𝐒𝐞𝐫𝐯𝐢𝐜𝐞 (𝐊𝐢𝐭𝐬, 𝐈𝐧𝐬𝐭𝐫𝐮𝐦𝐞𝐧𝐭𝐬), 𝐂𝐢𝐫𝐜𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 (𝐂𝐓𝐂, 𝐜𝐭𝐃𝐍𝐀, 𝐜𝐟𝐃𝐍𝐀), 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 (𝐍𝐆𝐒, 𝐏𝐂𝐑), 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 (𝐂𝐚𝐧𝐜𝐞𝐫 (𝐋𝐮𝐧𝐠, 𝐁𝐫𝐞𝐚𝐬𝐭, 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞), 𝐍𝐨𝐧-𝐜𝐚𝐧𝐜𝐞𝐫 (𝐍𝐈𝐏𝐓, 𝐈𝐧𝐟𝐞𝐜𝐭𝐢𝐨𝐮𝐬)), 𝐒𝐚𝐦𝐩𝐥𝐞 𝐓𝐲𝐩𝐞 (𝐁𝐥𝐨𝐨𝐝) - 𝐆𝐥𝐨𝐛𝐚𝐥 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐭𝐨 2029", is valued at an estimated USD 6.4 billion in 2024 and is projected to reach USD 11.3 billion by 2029 at a CAGR of 11.9% during the forecast period. The benefits offered by liquid biopsy in comparison to traditional incisional biopsy procedures, such as its non-invasive nature, cost savings, convenient disease monitoring, and early detection of cancer, have led to its widespread adoption among end users. As awareness of these benefits continues to grow, there is a notable shift towards the adoption of liquid biopsy across various medical disciplines. This growing recognition and acceptance of the advantages of liquid biopsy over conventional biopsy methods is serving as a catalyst for the rapid evolution and expansion of liquid biopsy products and services. 𝐄𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐢𝐬 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲: Novigenix SA miR Scientific, LLC Mursla Bio MultiplAI Health Nanostics Inc. Dxcover Enumera Molecular RealSeq Biosciences Fraunhofer IMM Apollo Hospitals Educational and Research Foundation (AHERF) Tethis S.p.A SmartCatch Noscendo GmbH Singlera Genomics Incorporated AccuraGen Atlantic Cancer Research Institute - Institut atlantique de recherche sur le cancer Apostle Inc Redbud Labs Cordance Medical Cancer Research UK National Biomarker Centre METHYS Dx Zinexts Life Science Corp. Genece Health Telo Genomics Senseera GENECAST Yourgene Health Canada IMBdx MetaSight Diagnostics DeltaBio QCDx IMSTAR Dx GeneCast Biotechnology Co., Ltd. HLB PANAGENE Co., LTD. Exsegen Genomics Cellomics International Limited ADELIS Technologies MiCareo, Inc. HaploX Biotechnology CytoGen, Inc.

The role of the European biotech innovation ecosystem in the development of innovative medicine Advanced therapy medicinal products (ATMPs) represent the next wave of innovation in biopharma. These products are novel therapeutics based on genes, tissues or cells, including gene therapy, somatic-cell therapy, and tissue engineering.49 These products have historically been focused on the orphan / rare disease space, although interviews with VC companies indicated that there are many companies looking to expand these therapies to reach a broader audience. ATMPs are particularly important as a signal for where innovation hubs will be concentrated in the future. However, Europe is falling behind the US regarding the development, funding and approval of these therapies. As of 2023, the EMA has approved 17 ATMPs, which are still active, while there are 21 marketed ATMPs available in the US. 50 Additionally, ATMP manufacturers face increased challenges post approval regarding market access and commercial take-up. Although Europe has historically been a leader in scientific discovery, this has not translated to this latest wave of innovation. Figure shows that the US clearly outperforms other regions, with over twice as many ATMP clinical trials taking place versus the EU between January 2020 and October 2023. In fact, the EU is also lagging China on this front, further placing emphasis on the need to accelerate the clinical trial process. ATMPs are a key measure of innovation from emerging and small biotech. Although the majority of ATMPs are owned by mature companies at launch, this does not reflect the originators of ATMPs, of which emerging and small biotech companies make up a significant portion

𝙀𝙢𝙚𝙧𝙜𝙞𝙣𝙜 𝙏𝙧𝙚𝙣𝙙𝙨 𝙞𝙣 𝙩𝙝𝙚 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 𝙎𝙚𝙘𝙪𝙧𝙚 𝙖 𝙁𝙍𝙀𝙀 𝙎𝙖𝙢𝙥𝙡𝙚: https://lnkd.in/g6QwVu9V The 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 is experiencing dynamic growth, fueled by advancements in medical technology and a deeper understanding of neuro-oncology. As we navigate through 2024, several key trends are shaping the landscape: 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙫𝙚 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙩𝙞𝙘 𝙏𝙤𝙤𝙡𝙨: Cutting-edge imaging technologies, such as advanced MRI and PET scans, are revolutionizing the early detection of brain tumors. These tools enhance accuracy, allowing for timely intervention and improved patient outcomes. 𝙏𝙖𝙧𝙜𝙚𝙩𝙚𝙙 𝙏𝙝𝙚𝙧𝙖𝙥𝙞𝙚𝙨 & 𝙋𝙧𝙚𝙘𝙞𝙨𝙞𝙤𝙣 𝙈𝙚𝙙𝙞𝙘𝙞𝙣𝙚: The shift towards personalized medicine is leading to the development of targeted therapies that address specific genetic mutations and molecular characteristics of brain tumors. This approach is significantly improving treatment efficacy and minimizing side effects. 𝙄𝙢𝙢𝙪𝙣𝙤𝙩𝙝𝙚𝙧𝙖𝙥𝙮 & 𝙉𝙤𝙫𝙚𝙡 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩𝙨: Emerging therapies, including immunotherapy and gene editing techniques, are showing promise in treating brain tumors that were previously considered resistant to conventional methods. These innovative treatments offer new hope for patients. 𝙆𝙚𝙮 𝙋𝙡𝙖𝙮𝙚𝙧𝙨: The brain tumor diagnosis & therapeutics industry comprises of various key market players such as Pfizer, Amgen, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novartis, Karyopharm Therapeutics Inc., Canon Medical Systems Corporation, Lantern Pharma Inc. (Nasdaq: LTRN), and others. 𝘼𝙘𝙘𝙚𝙨𝙨 𝙁𝙪𝙡𝙡 𝙍𝙚𝙥𝙤𝙧𝙩: https://lnkd.in/gGz6zwUT As we move forward, collaboration between researchers, clinicians, and industry leaders will be crucial in advancing treatments and improving patient care. Let’s continue to support innovation and drive progress in this vital field! #braintumor #neurooncology #medicalinnovation #healthcare #precisionmedicine #immunotherapy #markettrends #marketresearch #globalindustry